Table 6.

Adjuvant treatment according to hormone receptor status and age. Endocrine therapy is more frequently administered in HR+ patients, independently of age (χ ² = 699.89; 6 df; P < .0001).

		HT		CHT		CHT-HT
		N	%	N	%	N	%
ER+/PgR+	≤35	0	0	3	7.1	39	92.9
	36–40	10	9.5	8	7.6	87	82.9
	41–45	40	20.4	6	3.1	150	76.5
	46–50	78	23.9	5	1.5	243	74.5
ER+/PgR−	≤35	0	0	0	0	6	100.0
	36–40	1	5.6	1	5.6	16	88.9
	41–45	3	12.0	2	8.0	20	80.0
	46–50	10	29.4	2	5.9	22	64.7
ER−/PgR+	≤35	0	0	2	33.3	4	66.7
	36–40	0	0	0	0	5	100.0
	41–45	0	0	5	33.3	10	66.7
	46–50	3	15.8	5	26.3	11	57.9
ER−/PgR−	≤35	0	0	17	89.5	2	10.5
	36–40	0	0	29	93.5	2	6.5
	41–45	1	1.7	55	91.7	4	6.7
	46–50	0	0	65	95.6	3	4.4